Pakistani firm Nurin Pharma has received approval to build a new pharmaceutical plant in the Tashkent Pharma Park. The project, valued at approximately $20 million, involves the phased construction of a production facility on a 2.5-hectare site.
An official ceremony was held in the Tashkent Pharma Park to register Nurin Pharma (Pharmatec Pakistan) as a new participant in the innovative-scientific-production pharmaceutical cluster. Abdulla Azizov, Director of the Agency for the Development of the Pharmaceutical Industry, presented the company with the certificate confirming its participation. This establishes the legal basis for the implementation of the investment project within the cluster's territory.
Nurin Pharma plans to construct a modern pharmaceutical plant on a site area of 2.5 hectares. The estimated investment cost is approximately $20 million. The project will be implemented in phases in accordance with Good Manufacturing Practice (GMP) standards. The facility is intended to produce medicines for treating high blood pressure, type 2 diabetes, gastrointestinal diseases, cardiovascular diseases, and various infections.
The project is expected to create 145 new jobs. The initiative contributes to the further development of the pharmaceutical cluster in the Uzbek capital, which aims to attract international manufacturers to diversify and modernize local drug production.
Project: Nurin Pharma plant · Uzbekistan · Under construction · $20 m
Key facts
- Investment volume: approx. $20 million
- Site area: 2.5 hectares
- Planned jobs: 145
- Production standards: GMP (Good Manufacturing Practice)